Voquezna denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for voquezna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Voquezna as "Not FDA-Approved"

Voquezna (vonoprazan) is a potassium-competitive acid blocker (PCAB) that has received FDA approval for specific acid-related conditions. A "not FDA-approved" denial from UHC most commonly means the claim was processed against the wrong indication code, or the plan's system has not yet updated its formulary data to reflect the drug's approved status. It can also mean UHC believes the prescribed use falls outside the labeled indications — a distinction that is worth challenging with documentation.

## Why This Denial Is Appealable

If Voquezna was prescribed for an FDA-approved indication, this denial is factually incorrect and should be overturned on appeal. You have the right to a full internal appeal and, if that fails, an independent external review. Federal law gives you strong protections here:

• ACA §2719 / state external review: Most non-grandfathered individual and group plans must offer external review by an independent organization. The typical window to request external review is approximately four months from the internal denial notice — do not let this deadline pass.
• ERISA §503: If your coverage is employer-sponsored, ERISA requires a full-and-fair review of every adverse benefit determination, including the right to review all documents the plan relied on.
• Expedited review: If your condition is urgent, request an expedited internal appeal and expedited external review simultaneously — decisions are typically required within 72 hours.

## Documentation to Gather

• FDA approval confirmation: Print the current FDA label (available at DailyMed) showing the approved indications. Highlight the indication matching your prescription.
• Prescriber letter: A letter from your physician stating the specific FDA-approved indication being treated, why Voquezna was selected, and the clinical basis for the choice.
• Diagnosis documentation: Office notes and any relevant endoscopy or diagnostic reports confirming the diagnosis that maps to an approved indication.
• Denial document: Request UHC's complete denial rationale and the clinical criteria or policy it relied upon.

## Criteria-Mapping Approach

Build a simple two-column table in your appeal letter:

| UHC's stated reason for denial | Your response with supporting document | |---|---| | Drug not FDA-approved | FDA label (DailyMed, dated) showing approved indication X | | Indication mismatch (if alleged) | Office note + ICD-10 code matching approved label indication |

Address each basis for denial point-by-point. Close the letter by asking UHC to identify, in its response, any remaining basis for denial so you can address it at external review.

## Next Step

File your internal appeal in writing within UHC's stated deadline (check your Explanation of Benefits). Keep certified-mail or portal-submission proof. If the internal appeal is denied, immediately request external review — the external reviewer is independent of UHC and frequently overturns denials of FDA-approved drugs used for labeled indications.